

GRANADILLO PEDRO P
Form 4
September 19, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
GRANADILLO PEDRO P

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [HAE]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
400 WOOD ROAD
(Street)
BRAINTREE, MA 02184

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2018

Director 10% Owner
 Officer (give title below) Other (specify below)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock | 09/17/2018 | | M ⁽¹⁾ | | 8,196 | A | \$ 36.37 |
| Common Stock | 09/17/2018 | | M ⁽¹⁾ | | 6,573 | A | \$ 45.45 |
| Common Stock | 09/17/2018 | | M ⁽¹⁾ | | 10,353 | A | \$ 35.5 |
| Common Stock | 09/17/2018 | | S ⁽¹⁾ | | 1,502 | D | \$ 108.92 |
| Common Stock | 09/17/2018 | | S ⁽¹⁾ | | 3,696 | D | \$ 110.11 |

| | | | | | (4) | | | |
|--------------|------------|------------------|--------|---|--------------|--------|-----|---|
| Common Stock | 09/17/2018 | S ⁽¹⁾ | 13,183 | D | \$ 111.33 | 40,100 | (2) | D |
| | | | | | (5) | | | |
| Common Stock | 09/17/2018 | S ⁽¹⁾ | 11,812 | D | \$ 113.16 | 28,288 | (2) | D |
| | | | | | (6) | | | |
| Common Stock | 09/17/2018 | S ⁽¹⁾ | 631 | D | \$ 114.16 | 27,657 | (2) | D |
| | | | | | (7) | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Underlying Security (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| Non-qualified Stock Option (Right to Buy) | \$ 36.37 | 09/17/2018 | | M ⁽¹⁾ | 8,196 | 07/27/2013 ⁽⁸⁾ 07/27/2019 | Common Stock |
| Non-qualified Stock Option (Right to Buy) | \$ 45.45 | 09/17/2018 | | M ⁽¹⁾ | 6,573 | 07/24/2014 ⁽⁸⁾ 07/24/2020 | Common Stock |
| Non-qualified Stock Option (Right to Buy) | \$ 35.5 | 09/17/2018 | | M ⁽¹⁾ | 10,353 | 07/23/2015 ⁽⁸⁾ 07/23/2021 | Common Stock |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--------------------------------|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| | | X | | |

GRANADILLO PEDRO P
400 WOOD ROAD
BRAINTREE, MA 02184

Signatures

/s/ Thomas V. Powers, attorney-in-fact for Mr.
Granadillo

09/19/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction pursuant to an existing 10b5-1 trading plan.

(2) This number includes unvested restricted stock units previously reported.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.61 to \$109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.79 to \$110.55, inclusive.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.92 to 111.88, inclusive.

(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$112.51 to \$113.35, inclusive.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$114 to \$114.44, inclusive.

(8) Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.